Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture

These findings suggest that tumour stromal architecture may associate with acute tumour vascular response to VEGFR TKI, and this acute tumour vascular response may be a promising early predictive marker of response to VEGFR TKI in NSCLC.